{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:48:59Z","timestamp":1792244939433,"version":"4.4.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients exposed to dopamine agonists (DAs) may develop impulse-control disorders (ICDs), as shown in Parkinson\u2019s Disease. Patients with pituitary adenomas treated with DAs may also have a higher frequency of ICDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We compared the frequency of ICDs or impulsiveness in patients with pituitary adenomas treated with DAs versus patients with pituitary adenomas not exposed to DAs or healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Observational studies published in any language up to June 30\n                      <jats:sup>th<\/jats:sup>\n                      , 2026 were searched for in PubMed, EMBASE, EBSCO, LiLACS, SCOPUS, and WOS databases. We compared the occurrence of ICDs and impulsiveness scale scores between patients exposed to and not exposed to DAs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 14 studies identified, 10 reported the association between DAs and ICDs, and 6 reported the impact on the Barratt Impulsiveness Scale. DAs were significantly associated with ICDs (random-effects models, OR, 95% CI: 2.39, 1.78-3.21; I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%, n=1247; p&amp;lt;0.01) regardless of age, sex, cabergoline dose, or treatment duration. There were no indications of publication bias. Exposure to DAs was significantly associated with hypersexuality (3.11, 1.93-5.02, p&amp;lt;0.01, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%) and punding (2.53, 1.34-4.78, p&amp;lt;0.01, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a027.6%), but not with pathological gambling (1.94, 0.84-4.49, p=0.12, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00%) or compulsive shopping (1.46, 0.59-3.36, p=0.41, I\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a061.3%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with pituitary adenomas treated with DAs showed a higher frequency of ICDs. Studies to confirm these findings and investigate the risk factors for ICDs in this patient population are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1869083","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:29:59Z","timestamp":1786015799000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A systematic review and meta-analysis on impulse-control disorders in patients with pituitary adenomas exposed to dopamine agonists"],"prefix":"10.3389","volume":"17","author":[{"given":"Rodrigo","family":"Bilbao","sequence":"first","affiliation":[{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires (UBA)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Serralunga","sequence":"additional","affiliation":[{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires (UBA)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Loschiavo","sequence":"additional","affiliation":[{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires (UBA)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Altuna","sequence":"additional","affiliation":[{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires (UBA)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Manfre","sequence":"additional","affiliation":[{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires (UBA)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Capani","sequence":"additional","affiliation":[{"name":"Centro de Altos Estudios en Ciencias Humanas y de la Salud, Universidad Abierta Interamericana, Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas, CACEIHS. UAI-CONICET","place":["Buenos Aires, Argentina"]},{"name":"Instituto de Ciencias Biom\u00e9dicas, Facultad de Ciencias de la Salud, Universidad Aut\u00f3noma de Chile","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Otero-Losada","sequence":"additional","affiliation":[{"name":"Centro de Altos Estudios en Ciencias Humanas y de la Salud, Universidad Abierta Interamericana, Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas, CACEIHS. UAI-CONICET","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo J.","family":"Ponzo","sequence":"additional","affiliation":[{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires (UBA)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Perez-Lloret","sequence":"additional","affiliation":[{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad de Buenos Aires (UBA)","place":["Buenos Aires, Argentina"]},{"name":"Instituto Universitario de Ciencias de la Salud, Fundaci\u00f3n H.A Barcel\u00f3, Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","article-title":"The epidemiology of prolactinomas","volume":"8","author":"Ciccarelli","year":"2005","journal-title":"Pituitary"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2165\/11537810-000000000-00000","article-title":"Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease","volume":"24","author":"Perez-Lloret","year":"2010","journal-title":"CNS Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.4097","article-title":"Dopamine receptor agonist drugs and impulse control disorders","volume":"174","author":"Weiss","year":"2014","journal-title":"JAMA Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evidence-Based Ment Health"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01478-0","article-title":"Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study","volume":"44","author":"Beccuti","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s11102-026-01662-0","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-006-0668-0","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12902-022-01009-3","article-title":"The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study","volume":"22","author":"Ke","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/wnn.0000000000000320","article-title":"Effect of dopaminergic therapy on impulse control disorders in patients with a prolactinoma","volume":"36","author":"Ozdeniz Varan","year":"2023","journal-title":"Cognit Behav Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2020.101356","article-title":"Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas","volume":"55","author":"Ozkaya","year":"2020","journal-title":"Growth Hormone IGF Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-025-01517-0","article-title":"Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre","volume":"28","author":"Hamblin","year":"2025","journal-title":"Pituitary"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.579606","article-title":"Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas","volume":"11","author":"Hinojosa-Amaya","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.370452","article-title":"Impulse control disorders with short-term use of cabergoline in macroprolactinomas: a prospective study with a brief review of literature","volume":"71","author":"Sanjan","year":"2023","journal-title":"Neurol India"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58516","article-title":"Impulse control disorders in southern Iraqi patients medicated with cabergoline for prolactinoma","volume":"16","author":"Mohammad","year":"2024","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11102-026-01662-0","article-title":"Decision-making and impulsivity in cabergoline-treated prolactinoma: findings from Iowa Gambling, Go\/No-Go, and barratt scales","volume":"29","author":"G\u00f6kbulut","year":"2026","journal-title":"Pituitary"},{"key":"B24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11102-026-01693-7","article-title":"Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia","volume":"29","author":"Zerbinati","year":"2026","journal-title":"Pituitary"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0b013e31826e6e6d","article-title":"Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease","volume":"35","author":"Perez-Lloret","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2023.102910","article-title":"Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review","volume":"54","author":"Hamblin","year":"2023","journal-title":"Arch Med Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111363","article-title":"Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis","volume":"138","author":"Penchev","year":"2025","journal-title":"J Clin Neurosci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2018.02.004","article-title":"Impulse control disorders in Parkinson's disease patients with RLS: a cross sectional-study","volume":"48","author":"Marques","year":"2018","journal-title":"Sleep Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2026.1768251","article-title":"Neuropsychological aspects of impulse control disorders in Parkinson's disease","volume":"18","author":"Scanferla","year":"2026","journal-title":"Front Aging Neurosci"},{"key":"B30","article-title":"Epidemiologic and clinical updates on impulse control disorders: a critical review","volume":"256","author":"Dell'Osso","year":"2006","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11102-024-01383-2","article-title":"Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study","volume":"27","author":"Almalki","year":"2024","journal-title":"Pituitary"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac718","article-title":"A genetic assessment of dopamine agonist-induced impulse control disorder in patients with prolactinoma","volume":"108","author":"Sahin","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.93913758.x","article-title":"Familial influences on gambling behavior: an analysis of 3359 twin pairs","volume":"93","author":"Eisen","year":"1998","journal-title":"Addiction"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1037\/a0032161","article-title":"The Barratt Impulsiveness Scale-11: reassessment of its structure in a community sample","volume":"25","author":"Reise","year":"2013","journal-title":"Psychol Assess"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1869083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:30:00Z","timestamp":1786015800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1869083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":35,"alternative-id":["10.3389\/fendo.2026.1869083"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1869083","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1869083"}}